Four years ago we reviewed the place of anticholinergic drugs for the treatment of reversible airway narrowing. The newest of these, ipratropium bromide (Atrovent - Boehringer Ingelheim) had not then been marketed in Britain, but we quoted some conflicting results of studies with this drug in asthmatic and bronchitic patients.1 It is the only anti-cholinergic drug marketed alone as a metered-dose inhaler; others are available only as mixtures with sympathomimetics.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.